Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 5
2016 15
2017 14
2018 21
2019 30
2020 18
2021 5
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33789934

95 results
Results by year
Filters applied: . Clear all
Page 1
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, Oedegaard C, Saad A, Sandler I, Ben-Haim S, Domachevsky L, Berger R. Leibowitz R, et al. Oncologist. 2020 Sep;25(9):787-792. doi: 10.1634/theoncologist.2020-0100. Epub 2020 Jun 10. Oncologist. 2020. PMID: 32430954 Free PMC article.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
[PSMA-targeted radioligand therapy in prostate cancer].
Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M. Heck MM, et al. Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Urologe A. 2017. PMID: 27885457 Review. German.
95 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page